TechNavio today launched its report Global Hepatitis Drugs Market 2011-2015 based on an in-depth analysis covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said: ”Vendors are increasingly forming strategic alliances with other vendors to market their manufactured drugs to acquire a wider market share in the Global Hepatitis Drugs market. For instance Merck and Co. Inc. has formed a partnership with Roche Holding Ltd. to market its hepatitis drugs to increase its market share. Similarly, Vertex Pharmaceuticals Ltd. has a partnership with Johnson and Johnson Services Inc. to market its hepatitis drugs outside the US.”
According to the report, increasing prevalence of hepatitis infection worldwide is expected to be a major factor which will drive the growth of the Global Hepatitis Drugs market over the period 2011-2015.
Further, the report discusses that one of the major challenges is the shortage of hepatitis drugs to meet the demand of the market, especially in the developing and less-developed countries.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit https://www.technavio.com/content/global-hepatitis-drugs-market-2011-2015
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic market research reports on niche and emerging technologies. For more information on our Healthcare market research, please visit https://www.technavio.com/healthcare
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Research Report – Global Hepatitis Drugs Market 2011-2015
